title: Salvage therapy for ovarian cancer.
abstract: The majority of patients with ovarian cancer will relapse after initial chemotherapy and will be candidates for salvage treatment. Currently, five agents show clear activity in patients with platinum- and paclitaxel-resistant disease: topotecan, oral etoposide, liposomal doxorubicin, gemcitabine, and, possibly, docetaxel. In addition, other agents have activity in platinum-resistant patients: vinorelbine, tamoxifen, ifosfamide, altretamine, 5-fluorouracil with leucovorin, and, possibly, irinotecan. Furthermore, selected patients may benefit from other therapeutic approaches such as surgery or radiation therapy.
authors: Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, MS 34, Los Angeles, CA 90089-9177, USA.
authors: A A
authors: AA
authors: Garcia
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy; D016019:Survival Analysis